Sign In
Buy SPRC
$6.92
-0.0500 (-0.717%)
At Close: Jun 23, 2026
TEL AVIV, Israel, Dec. 31, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies t
S&P 500 Edges Lower, SciSparc Shares Surge
02:36pm, Thursday, 26'th Dec 2024
U.S. stocks traded slightly lower toward the end of trading, with the S&P 500 edging lower on Thursday.
SciSparc: AutoMax Announces $13 Million First Delivery of JAC Vehicles Following Regulatory Approval for Direct Importation
06:46am, Thursday, 26'th Dec 2024
TEL AVIV, Israel, Dec. 26, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), announced that AutoMax Motors Ltd., (“AutoMax”), a leading automotive importer and distr
According to the LOI , SciSparc's pharmaceuticals assets are valued at approximately US $11. 6 million
FDA confirm s that SciSparc's study may proceed only a month after application submission
SciSparc Signs Non-Binding Letter of Intent to Sell Stake in MitoCareX
09:05am, Thursday, 26'th Sep 2024
The intended selling valuation represents an increase of 47 % from the valuation at the time of SciSparc's initial investment in MitoCareX Bio
SciSparc Receives FDA Approval to Initiate Phase IIb Clinical Trial for Tourette Syndrome Treatment
08:17am, Monday, 23'rd Sep 2024
FDA confirm s that SciSparc's study may proceed following the application submission a month ago
SciSparc Takes Major Step Forward with IND Application submitted to the FDA for Phase IIb Clinical Trial for Tourette Syndrome Treatment
04:09pm, Wednesday, 18'th Sep 2024
Yale Child Study Center at the Yale School of Medicine in the USA, Hannover Medical School in Germany and Tel Aviv Sourasky Medical Center in Israel will take part in the trial
This innovative drug combination treatment focuses on boosting safety and efficacy in mental health and addiction care TEL AVIV, Israel, Sept. 16, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd.
SciSparc Advances $1.85 million Loan to AutoMax, Following AutoMax's Direct Import Agreement with Major Chinese Vehicle Manufacturer
07:40am, Wednesday, 11'th Sep 2024
To date, SciSparc has advanced $4.25 million to Automax under the Bridge Loan agreement and amendments thereto
Pioneering Therapeutic Approach Aims to Enhance Safety and Efficacy in Mental Health and Addiction Treatments TEL AVIV, Israel, Sept. 06, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd.
SciSparc-Clearmind Medicine Collaboration Leads to Publication of Application for Innovative Ketamine-Based Combination
04:25pm, Thursday, 29'th Aug 2024
TEL AVIV, Israel, Aug. 29, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies t
SciSparc Grants Global Rights for Pain Therapy to Biotech Company in Agreement Worth up to $6 Million
08:55am, Wednesday, 28'th Aug 2024
SciSparc would be entitled to receive consideration valued at $3 million in Polyrizon securities, as well as potential milestone fees of approximately $3 million in cash
SciSparc Submitted IND Application to the FDA for SCI-110 Phase IIb Clinical Trial for Patients with Tourette Syndrome
04:09pm, Friday, 23'rd Aug 2024
SciSparc to conduct the trial at the Yale Child Study Center at the Yale School of Medicine in the USA, Hannover Medical School in Germany and Tel Aviv Sourasky Medical Center in Israel
SciSparc: MitoCareX Appointed Professor Nir Peled, Seasoned Oncologist, to its Scientific Advisory Board
08:12am, Thursday, 22'nd Aug 2024
Professor Peled is the Director of the Oncology Department at the Shaare Zedek Medical Center , Jerusalem , Israel, and the head of the Global Multidisciplinary Practice Standards Committee (GMPSC) of
